Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) rose 7.6% during mid-day trading on Friday . The stock traded as high as $9.26 and last traded at $9.44. Approximately 659,493 shares changed hands during trading, a decline of 32% from the average daily volume of 963,540 shares. The stock had previously closed at $8.77.
Analysts Set New Price Targets
RZLT has been the subject of several recent research reports. BTIG Research restated a "buy" rating and set a $17.00 target price on shares of Rezolute in a research report on Thursday, September 18th. Guggenheim restated a "buy" rating and set a $15.00 target price on shares of Rezolute in a research note on Monday. Maxim Group increased their target price on Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, September 18th. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Rezolute in a research report on Wednesday, September 3rd. Finally, Wedbush reaffirmed an "outperform" rating and set a $12.00 target price on shares of Rezolute in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to data from MarketBeat, Rezolute currently has a consensus rating of "Buy" and an average target price of $14.50.
Read Our Latest Stock Analysis on RZLT
Rezolute Trading Up 6.5%
The firm's 50-day moving average price is $6.88 and its 200-day moving average price is $4.86. The stock has a market capitalization of $848.17 million, a PE ratio of -9.63 and a beta of 0.03.
Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, equities research analysts predict that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.
Institutional Trading of Rezolute
Hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. bought a new stake in shares of Rezolute in the 4th quarter worth about $342,000. Jeppson Wealth Management LLC bought a new stake in shares of Rezolute in the 1st quarter worth about $35,000. XTX Topco Ltd bought a new stake in shares of Rezolute in the 1st quarter worth about $95,000. American Century Companies Inc. lifted its holdings in shares of Rezolute by 5.2% in the 1st quarter. American Century Companies Inc. now owns 67,925 shares of the company's stock worth $197,000 after acquiring an additional 3,334 shares during the last quarter. Finally, Pale Fire Capital SE lifted its holdings in shares of Rezolute by 9.1% in the 1st quarter. Pale Fire Capital SE now owns 47,122 shares of the company's stock worth $137,000 after acquiring an additional 3,935 shares during the last quarter. 82.97% of the stock is currently owned by hedge funds and other institutional investors.
Rezolute Company Profile
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
